Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea.
Adv Exp Med Biol. 2024;1456:307-331. doi: 10.1007/978-981-97-4402-2_16.
The chapter provides an in-depth analysis of digital therapeutics (DTx) as a revolutionary approach to managing major depressive disorder (MDD). It discusses the evolution and definition of DTx, their application across various medical fields, regulatory considerations, and their benefits and limitations. This chapter extensively covers DTx for MDD, including smartphone applications, virtual reality interventions, cognitive-behavioral therapy (CBT) platforms, artificial intelligence (AI) and chatbot therapies, biofeedback, wearable technologies, and serious games. It evaluates the effectiveness of these digital interventions, comparing them with traditional treatments and examining patient perspectives, compliance, and engagement. The integration of DTx into clinical practice is also explored, along with the challenges and barriers to their adoption, such as technological limitations, data privacy concerns, ethical considerations, reimbursement issues, and the need for improved digital literacy. This chapter concludes by looking at the future direction of DTx in mental healthcare, emphasizing the need for personalized treatment plans, integration with emerging modalities, and the expansion of access to these innovative solutions globally.
这一章深入分析了数字疗法（DTx）作为一种治疗重度抑郁症（MDD）的革命性方法。它讨论了 DTx 的演变和定义、它们在各个医学领域的应用、监管方面的考虑因素，以及它们的好处和局限性。这一章广泛涵盖了用于 MDD 的 DTx，包括智能手机应用程序、虚拟现实干预、认知行为疗法（CBT）平台、人工智能（AI）和聊天机器人疗法、生物反馈、可穿戴技术和严肃游戏。它评估了这些数字干预措施的有效性，将其与传统治疗方法进行了比较，并考察了患者的观点、依从性和参与度。还探讨了 DTx 如何融入临床实践，以及它们在采用过程中面临的挑战和障碍，如技术限制、数据隐私问题、伦理考虑、报销问题以及提高数字素养的需求。最后，这一章展望了数字疗法在精神保健领域的未来方向，强调需要个性化的治疗计划、与新兴模式的整合，以及在全球范围内扩大这些创新解决方案的可及性。
